Bispecific antibodies targeting BCMA, GPRC5d and FcRH5 on myeloma cells and CD3 on T cells are the most advanced in clinical development and show efficacy in RRMM patient populations previously exposed to other T-cell directed therapies, even after sequentially targeting the same plasma cell antigen. Here, TNFRSF17 is linked to plasma cell myeloma.